

Pharmacy and Therapeutics Committee

Meeting Minutes

Thursday, July 19, 2018
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 125

Committee Members Present:

Clinton Sheffield, MD
Susan Siegfried, MD
Elizabeth Young, PharmD
Jake Jones, MD

Bryan Larson, PharmD
McKay Robinson, PharmD
Cole Sloan, PharmD

Committee Members Excused:

Clayton Grace, RPh

Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Strohecker, PharmD, Pharmacy
Director
Joe Busby, RPh, MBA

Robyn Seely, PharmD
Merelynn Berrett, RN

University of Utah Drug Regimen Review Center Staff Presenter:

Valerie Gonzales, PharmD

Other Individuals Present:

Margaret Fisher, Novo Nordisk
Jennifer Lauper, BMS
John Sandstrom, Shire
Kevin Kassabian, Shire
Rob Meier, Pfizer
Bill Robie, NHF
Lynn Barker, Octapharma, USA
Alex Bitting, Bioverativ
Kristen Rowe, Bioverativ
Folger Tuggle, Bioverativ
Judith Vensak, CSL Behring
Kris McFalk, CSL Behring
Tamara Pineault, CSL Behring
Dawn Bina, Novo Nordisk
Shea Wilson, Molina
Susan Kelly, Spark Therapeutics
Lori Howarth, Bayer

Joanne Yasuda, Pfizer
Corinne Copeland, Alexion
Soheyla Azizi, Eisai
Don McCaffrey, Vertex
Deron Grothe, Teva
Michelle Bice, Gilead
Sabrina Blackwell, Gilead
Betty Charz, Gilead
Lee Stout, Chiesi
Trevor Smith, DOH
Randy Crocker, Molina
Lori Blackner, Pfizer
Joanne LaFleur, U of U
Cody Ball, Select Health
Bret Fergusen, Pfizer
John Curless, DOH

Meeting conducted by: Clinton Sheffield

1. **Welcome & Housekeeping:** Committee Chair opened the meeting announced a quorum.
 - a. Clinton Sheffield nominated McKay Robinson as the P&T Committee chair for the next year (starting at next meeting). Bryan Larson seconded the motion, Unanimous approval, motion passed.
 - b. The committee discussed starting the meetings earlier and holding longer, but less frequent meetings. The committee members were generally in favor of starting at 7:00 am instead of 7:15 am with the same end time. Committee members also generally favored fewer meetings with more topics covered per meeting.
2. **Review and Approval of June Minutes:** Bryan Larson made a motion to approve the minutes from June. Clinton Sheffield seconded the motion. All in favor, motion passed.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Sublocade.
4. **Accountable Care Organization (ACO) Update: Report on Methodologies for Preferred Drug List Development:**
 - a. Molina..... Shea Wilson, RPh
5. **Hemophilia Factor VIII:** (Advate, Adynovate, Afstyl, Eloctate, Helixate FS, Hemofil M, Koate, Koate DVI, Kogenate FS, Kovaltry, Monoclate P, Novoeight, Nuwiq, Recombinate, Xyntha). Valerie Gonzales presented a review of Hemophilia Factor VIII products. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
6. **Public Comment:**
 - a. Bryan Larson read a letter from Bayer in lieu of Trina Ballard who was unable to attend the meeting. This letter gave information about Kovaltry.
 - b. Margaret Fisher from Novo Nordisk presented information pertaining to Novoeight and advocated for open availability of all factor products.
 - c. Kevin Kassabian from Shire presented information pertaining to Advate, Adynovate, and myPKFiT software.
 - d. Judi Vensak from CSL Behring presented information pertaining to Afstyl.
 - e. Bill Robie from the National Hemophilia Foundation expressed opposition to the placement of hemophilia drugs on the PDL and advocated for open availability of all factor products.
 - f. Alex Bitting from Bioverative presented information pertaining to Eloctate.
 - g. Joanne Yasuda from Pfizer presented information pertaining to Xyntha.
 - h. Lynn Barker from Octapharma, USA presented information pertaining to Nuwiq.
 - i. Bryan Larson read a letter from the Utah Hemophilia Foundation advocating for patient choice and open availability of all factor products.
 - j. Bryan Larson read a letter from George Rodgers, MD encouraging the committee to strongly consider patient choice in the review of formulary products.

7. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States' Medicaid programs.
8. **Committee Discussion:**
 - a. Bryan Larson made a motion to allow a grandfathering clause with a look back of 90 days be incorporated into the PDL for this class. Elizabeth Young seconded the motion. Unanimous approval, motion passed.
 - b. Bryan Larson made a motion that all agents are equally safe and efficacious for inclusion on the PDL and that at least 4 agents should be preferred. No vote on motion, motion abandoned.
 - c. Bryan Larson made a motion that hemophilia Factor VIII products are equally safe and efficacious for inclusion on the PDL and that at least 2 human factors and at least 4 recombinant should be preferred on the PDL. Jake Jones seconded the motion. Unanimous approval, motion passed.
 - d. Bryan Larson made a motion that "long acting" is defined as two times per week dosing or less frequent and that at least one long acting and one short acting agent be preferred on the PDL. McKay Robinson seconded the motion. Unanimous approval, motion passed.
9. **Public Meeting Adjourned:** Clinton Sheffield motioned to close the meeting. McKay Robinson seconded the motion. Unanimous Approval.
10. **Next meeting is scheduled for** September 20, 2018 Hemophilia Factor IX, Combination Factor VIII/VWF.

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>